Standard InChI: InChI=1S/C21H22ClFN4O3/c1-28-19-11-15-18(12-20(19)30-9-6-27-4-7-29-8-5-27)24-13-25-21(15)26-17-3-2-14(22)10-16(17)23/h2-3,10-13H,4-9H2,1H3,(H,24,25,26)
VEGF-receptor 2 and Fibroblast growth factor receptor 1 50 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: No
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Small molecule
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 432.88
Molecular Weight (Monoisotopic): 432.1364
AlogP: 3.89
#Rotatable Bonds: 7
Polar Surface Area: 68.74
Molecular Species: NEUTRAL
HBA: 7
HBD: 1
#RO5 Violations: 0
HBA (Lipinski): 7
HBD (Lipinski): 1
#RO5 Violations (Lipinski): 0
CX Acidic pKa:
CX Basic pKa: 6.20
CX LogP: 3.69
CX LogD: 3.66
Aromatic Rings: 3
Heavy Atoms: 30
QED Weighted: 0.61
Np Likeness Score: -1.75
References
1.Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors., 45 (6):[PMID:11881999][10.1021/jm011022e]
2.Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors., 42 (26):[PMID:10639280][10.1021/jm990345w]
